Toodles
3 months ago
I don't know what type of snow-job Dalton gave these guys, but IMO he is sure hurting them having him on the Advisory Board
The case is worth reading- CV2019 008314 - Crognale invested in AgriMed and was placed on the Board, then in 2018 Dalton got him to invest $50k in WellnessRx and their CBD patch under bogus pretences, including the prospect of UNVC and WellnessRx merging through a reverse merger - with WellnessRx being the surviving entity.
Dalton basically made fraudulent misrepresentations, got Crognale's investment, subsequently lied to him about delays in the development and progress of the patch, then finally ghosted him - and delivered nothing... seems to be his standard operating procedure.
The case had many counts: Fraudulent Securities Practices, Fraud in Inducement, Negligent Misrepresentation, Breach of Fiduciary Duty, Constructive Fraud, Conversion - Dalton's attorney had their Preliminary Objections rejected by the Court who sided with the Plaintiff, and they ultimately chose to settle rather than face trial.
Dalton was making so many unfounded claims in order to get the investment, he even suggested he had an agreement with Rite-Aid to stock the WellnessRx CBD patches in their stores. Which there never were any patches.
https://delcopublicaccess.co.delaware.pa.us/
CHEERS
Toodles
3 months ago
Only thing is they have a small problem with their distribution of the products. (David Dalton CEO of Univec Inc) claims to own PI PREVENTION CARE LLC, who IRME signed a distribution agreement with. Dalton has no creditability at all, he has totally bankrupted his company UNVC.
https://contracts.justia.com/companies/ir-med-inc-12979/contract/260505/
Prior to the Commercial Launch Date, the Distributor is to invest such resources as is reasonable such that upon the occurrence of the Commercial Launch Date there will be a commercially reasonable distribution network in place for the immediate marketing of the Product. On June 18, 2024, we provided the Distributor with a notice of the Commercial Launch Date of September 20, 2024. On July 16, 2024, we provided a notice of breach of contract to the Distributor following his lack of response to our Commercial Launch Date notice.
I'm certain IRME can get a reputable Co. for distribution, only they may have to give up some valuable assets in doing so now.
We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances,
licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or
other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidates or
to grant licenses on terms that may not be favorable to us.
CHEERS
AskMuncher
3 years ago
$IRME IR-Med to Announce 2022 Goals: Anticipated POC Results, File for FDA Clearance and up Listing to the OTCQB
Press Release | 01/12/2022
IR-Med (OTC: IRME) (“Company” or “the Company”) is proud to announce a series of corporate updates to its investors regarding the medical, financial, and corporate status of the company. Amongst other things, IR-Med announces that starting H1 of 2022 the Company will initiate a usability test to demonstrate the capabilities of its proprietary “PressureSafe” device. The Company updates that it has received an IRB-Helsinki Committee approval from one of Israel’s largest geriatric hospitals, “Beit Rivka” to conduct the test in their facility.
The Company also updates its intention to apply for premarket submission with the FDA (510 k) on H1 2022, backed with their intention to start market-penetration in the United States, subject to FDA’s approval, aimed at Q4 2022. The Company announces that it has appointed its business development team to start engaging with nursing homes and geriatric centers for pre-sale negotiations.
The Company announces it has applied for OTCQB up listing with the OTC Markets Group, that given the fact that IR-Med is having audited annual financials prepared in accordance with U.S. GAAP by a PCAOB auditor and maintains a Verified Company Profile at OTCMarkets.com, should be approved.
“I am proud of our team and of the progress we have made during the Covid-19 pandemic related uncertainty across all corners of the globe”, said Chief Executive Officer Dr. Rom Eliaz and added that “while the pandemic has presented, and continues to present, many challenges that are out of our control, we remain resolute and focused on that which is within our control, including our operational, clinical and regulatory work. We continue to make progress on all fronts and firmly believe that we are on the right path towards meaningful, value-adding milestones and transformational catalysts”.
The company also announces that Dolos Consultancy, LTD has been retained to provide investors and public relations relation and intelligence services to company, alongside social media amplification. Dolos Consultancy LTD is one the leading corporate strategy, intelligence gathering, investors analysis and capital advisories in the market. Dolos is working with a network of investors, family offices and venture capitalists, and is retained to support and accompany IR-Med in both Investors relations and market intelligence. Dolos has agreed to comply with all applicable securities laws and the policies of the OTC and SEC in providing the Services.
About IR-Med
IR-Med Inc., is developing non-invasive spectrographic analysis technology, allowing healthcare professions to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. The first product under development is, a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone and which calibrated personally to each patient’s skin, primarily caused by prolonged pressure associated with bed confinement. IR-med skin-device-interphase development of personalized medical devices allows high accuracy readings from the human body in a non-invasive method, that may Confidential Page 1 of 1 Yahalom 20, Z.H.R Industrial Zone PO Box 143, Rosh Pina, Israel 1231400 Tel: (+972) 04-6555054 Fax: (+972) 04-6104976 www.ir-medical.com provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes.
Currently, IR-med holds patents protecting its innovation in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue. The company is in preliminary process of examining the filing of additional patents applications.
Safe Harbor Statement / Forward-Looking Statements
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of IR-Med are subject to many factors including, but not limited to, the sufficiency or working capital and our ability to raise the capital needed to fund our development efforts, timing of product development, FDA approval/clearance of products in development, customer acceptance of our products in the market, the introduction of competitive products, the impact of any product liability or other adverse litigation, commercialization and technological difficulties, successful up-list to OTCQB, and the other risks identified in the S-1 resale registration statement filed with the Securities and Exchange Commission. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005758/en/
AskMuncher
4 years ago
$IRME IR-Med, Inc. Announces FINRA Approval of Name Change and Ticker Symbol Change to “IRME”
Press Release | 01/20/2021
New York, NY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- IR-Med, Inc, (OTC: IRME) (the “Company” or “IR-Med”) announced today that the Financial Industry Regulatory Authority, Inc. (“FINRA”) has approved the Company’s name change to “IR Med, Inc.” (from International Display Advertising, Inc.) and changed its ticker symbol to “IRME”. These corporate actions will be effective as of the open of trading on January 20, 2021. The new CUSIP number for the common stock will be 46265R103. These changes follow the Company’s announcement, in December 2020, of the successful completion of a share exchange transaction with I.R Med Ltd., an Israeli company, pursuant to which I.R Med Ltd became a wholly-owned subsidiary of the Company.
Commenting on the actions, Limor Davidson Mund, Chief Executive Officer of the Company, stated: “These changes represent a deliberate and strategic rebranding effort. We are excited to now be operating under a name that is reflective of our core business”.
About the IR-Med
IR-Med is a development stage company currently focused on the development and application of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address common medical ailments. Initially I.R Med’s technologies are designed to address the early detection of pressure injuries (PI) and the detection and diagnosis of ear infection, primarily in children. For more information visit http://www.ir-medical.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials and obtain approvals for the commercialization of any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The Company does not undertake any obligation to publicly update any forward looking statement. The Company is not subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Company Contact:
Limor Davidson Mund
ir@ir-medical.com
AskMuncher
4 years ago
$IDAD INTERNATIONAL DISPLAY ADVERTISING, INC. ANNOUNCES COMPLETION OF REVERSE MERGER AND CLOSING OF $2.2 MILLION PRIVATE PLACEMENT
Press Release | 12/29/2020
New York, NY , Dec. 29, 2020 (GLOBE NEWSWIRE) -- International Display Advertising, Inc. (OTCPINK: IDAD) announced today its successful completion of a share exchange transaction with I.R Med Ltd., an Israeli company, pursuant to which I.R Med Ltd became a wholly-owned subsidiary of the Company. The combined entity will focus on the business of I.R Med, a development stage company currently focused on the development of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address the diagnosis of common medical ailments. Initially, I.R Med’s technologies are designed to address the early detection of pressure injuries and the detection and diagnosis of ear infection, primarily in children.
The Company also announced today that it has consummated closing of a private placement with gross proceeds of approximately $2.2 million for the issuance and sale of 3,446,875 units of Company securities, where each unit is comprised of two shares of the Company’s common stock and one common stock purchase warrant for an additional share of common stock. The warrant is exercisable for a three year period at a per share exercise price of $0.64. The per unit purchase price is $0.64. Proceeds from the private placement will be used primarily to advance the combined company’s proprietary product portfolio and for general corporate purposes.
The Company issued to the former shareholders of IR Med 31,043,945 shares of common stock in exchange for the outstanding capital stock of I.R Med. The Company will also be issuing to the investors in the closing of the Private Placement 6,893,750 shares of common stock and three year warrants for the purchase of an aggregate of 3,446,875 additional shares of common stock. The Company has applied to the Financial Industry Regulatory Authority (FINRA) to have its corporate name changed to IR-Med, Inc.
“IR Med is developing a revolutionary diagnostic platform addressing some of the most common medical challenges, and I am honored to have been selected to lead the company” said Limor Davidson Mund, the Company’s newly appointed Chief Executive Officer. "While we will need to raise additional funds to realize our business plan, the Private Placement proceeds provides the capital to commence our business plan and further the development of our initial medical devices."
Prior to her role as CEO, Ms. Davidson Mund served as CEO, COO and marketing executive in various medical and ICT startups, including Wiser Market, Perytons, OZ Recovery Technologies and Biomedicom. Ms. Davidson Mund holds B.A in Computer Science and Economics with honors and M.B.A with honors, both from Tel Aviv University.
“We are very excited about the completion of the reverse merger and securing the proceeds, which allows us to further develop I.R Med technology and bring it to the market” said Yoram Drucker, the Company President, “we are delighted to have Ms. Davidson Mund as our new CEO, she has very significant business and technology experience and the drive to help us turn our unique technology into successful products.”
Summary of Transaction
The Company consummated the private placement following the completion of the share exchange transaction, pursuant to which I.R Med Ltd. became a wholly-owned subsidiary of the Company.
In connection with the private placement, the Company has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act of 1933, as amended, covering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the warrants issued in the private placement as well as certain of the shares issued in the share exchange. These securities have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.
Effective with the completion of the share exchange, the Board of Directors of the Company consists of Yoram Drucker, David Lazar, Oded Bashan, Ohad Bashan, Aharon Klein, Ron Mayron, and Yaniv Cohen.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IR Med Ltd.
I.R Med Ltd is a development stage company currently focused on the development and application of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address common medical ailments. Initially I.R Med’s technologies are designed to address the early detection of pressure injuries (PI) and the detection and diagnosis of ear infection, primarily in children. For more information visit http://www.ir-medical.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The Company does not undertake any obligation to publicly update any forward looking statement. Neither the Company nor I.R MED are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Company Contact:
Limor Davidson Mund
ir@ir-medical.com
AskMuncher
4 years ago
$IDAD INTERNATIONAL DISPLAY ADVERTISING, INC. ANNOUNCES COMPLETION OF REVERSE MERGER AND CLOSING OF $2.2 MILLION PRIVATE PLACEMENT
Press Release | 12/29/2020
New York, NY , Dec. 29, 2020 (GLOBE NEWSWIRE) -- International Display Advertising, Inc. (OTCPINK: IDAD) announced today its successful completion of a share exchange transaction with I.R Med Ltd., an Israeli company, pursuant to which I.R Med Ltd became a wholly-owned subsidiary of the Company. The combined entity will focus on the business of I.R Med, a development stage company currently focused on the development of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address the diagnosis of common medical ailments. Initially, I.R Med’s technologies are designed to address the early detection of pressure injuries and the detection and diagnosis of ear infection, primarily in children.
The Company also announced today that it has consummated closing of a private placement with gross proceeds of approximately $2.2 million for the issuance and sale of 3,446,875 units of Company securities, where each unit is comprised of two shares of the Company’s common stock and one common stock purchase warrant for an additional share of common stock. The warrant is exercisable for a three year period at a per share exercise price of $0.64. The per unit purchase price is $0.64. Proceeds from the private placement will be used primarily to advance the combined company’s proprietary product portfolio and for general corporate purposes.
The Company issued to the former shareholders of IR Med 31,043,945 shares of common stock in exchange for the outstanding capital stock of I.R Med. The Company will also be issuing to the investors in the closing of the Private Placement 6,893,750 shares of common stock and three year warrants for the purchase of an aggregate of 3,446,875 additional shares of common stock. The Company has applied to the Financial Industry Regulatory Authority (FINRA) to have its corporate name changed to IR-Med, Inc.
“IR Med is developing a revolutionary diagnostic platform addressing some of the most common medical challenges, and I am honored to have been selected to lead the company” said Limor Davidson Mund, the Company’s newly appointed Chief Executive Officer. "While we will need to raise additional funds to realize our business plan, the Private Placement proceeds provides the capital to commence our business plan and further the development of our initial medical devices."
Prior to her role as CEO, Ms. Davidson Mund served as CEO, COO and marketing executive in various medical and ICT startups, including Wiser Market, Perytons, OZ Recovery Technologies and Biomedicom. Ms. Davidson Mund holds B.A in Computer Science and Economics with honors and M.B.A with honors, both from Tel Aviv University.
“We are very excited about the completion of the reverse merger and securing the proceeds, which allows us to further develop I.R Med technology and bring it to the market” said Yoram Drucker, the Company President, “we are delighted to have Ms. Davidson Mund as our new CEO, she has very significant business and technology experience and the drive to help us turn our unique technology into successful products.”
Summary of Transaction
The Company consummated the private placement following the completion of the share exchange transaction, pursuant to which I.R Med Ltd. became a wholly-owned subsidiary of the Company.
In connection with the private placement, the Company has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act of 1933, as amended, covering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the warrants issued in the private placement as well as certain of the shares issued in the share exchange. These securities have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.
Effective with the completion of the share exchange, the Board of Directors of the Company consists of Yoram Drucker, David Lazar, Oded Bashan, Ohad Bashan, Aharon Klein, Ron Mayron, and Yaniv Cohen.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IR Med Ltd.
I.R Med Ltd is a development stage company currently focused on the development and application of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address common medical ailments. Initially I.R Med’s technologies are designed to address the early detection of pressure injuries (PI) and the detection and diagnosis of ear infection, primarily in children. For more information visit http://www.ir-medical.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The Company does not undertake any obligation to publicly update any forward looking statement. Neither the Company nor I.R MED are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Company Contact:
Limor Davidson Mund
ir@ir-medical.com
wingtrade
4 years ago
INTERNATIONAL DISPLAY ADVERTISING, INC. ANNOUNCES COMPLETION OF REVERSE MERGER AND CLOSING OF $2.2 MILLION PRIVATE PLACEMENT
New York, NY , Dec. 29, 2020 (GLOBE NEWSWIRE) -- International Display Advertising, Inc. (OTCPINK: IDAD) announced today its successful completion of a share exchange transaction with I.R Med Ltd., an Israeli company, pursuant to which I.R Med Ltd became a wholly-owned subsidiary of the Company. The combined entity will focus on the business of I.R Med, a development stage company currently focused on the development of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address the diagnosis of common medical ailments. Initially, I.R Med’s technologies are designed to address the early detection of pressure injuries and the detection and diagnosis of ear infection, primarily in children.
The Company also announced today that it has consummated closing of a private placement with gross proceeds of approximately $2.2 million for the issuance and sale of 3,446,875 units of Company securities, where each unit is comprised of two shares of the Company’s common stock and one common stock purchase warrant for an additional share of common stock. The warrant is exercisable for a three year period at a per share exercise price of $0.64. The per unit purchase price is $0.64. Proceeds from the private placement will be used primarily to advance the combined company’s proprietary product portfolio and for general corporate purposes.
The Company issued to the former shareholders of IR Med 31,043,945 shares of common stock in exchange for the outstanding capital stock of I.R Med. The Company will also be issuing to the investors in the closing of the Private Placement 6,893,750 shares of common stock and three year warrants for the purchase of an aggregate of 3,446,875 additional shares of common stock. The Company has applied to the Financial Industry Regulatory Authority (FINRA) to have its corporate name changed to IR-Med, Inc.
“IR Med is developing a revolutionary diagnostic platform addressing some of the most common medical challenges, and I am honored to have been selected to lead the company” said Limor Davidson Mund, the Company’s newly appointed Chief Executive Officer. "While we will need to raise additional funds to realize our business plan, the Private Placement proceeds provides the capital to commence our business plan and further the development of our initial medical devices."
Prior to her role as CEO, Ms. Davidson Mund served as CEO, COO and marketing executive in various medical and ICT startups, including Wiser Market, Perytons, OZ Recovery Technologies and Biomedicom. Ms. Davidson Mund holds B.A in Computer Science and Economics with honors and M.B.A with honors, both from Tel Aviv University.
“We are very excited about the completion of the reverse merger and securing the proceeds, which allows us to further develop I.R Med technology and bring it to the market” said Yoram Drucker, the Company President, “we are delighted to have Ms. Davidson Mund as our new CEO, she has very significant business and technology experience and the drive to help us turn our unique technology into successful products.”
Summary of Transaction
The Company consummated the private placement following the completion of the share exchange transaction, pursuant to which I.R Med Ltd. became a wholly-owned subsidiary of the Company.
In connection with the private placement, the Company has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act of 1933, as amended, covering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the warrants issued in the private placement as well as certain of the shares issued in the share exchange. These securities have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.
Effective with the completion of the share exchange, the Board of Directors of the Company consists of Yoram Drucker, David Lazar, Oded Bashan, Ohad Bashan, Aharon Klein, Ron Mayron, and Yaniv Cohen.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IR Med Ltd.
I.R Med Ltd is a development stage company currently focused on the development and application of Infra-Red (IR) and Artificial Intelligence (AI) technologies to address common medical ailments. Initially I.R Med’s technologies are designed to address the early detection of pressure injuries (PI) and the detection and diagnosis of ear infection, primarily in children. For more information visit http://www.ir-medical.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business plan and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The Company does not undertake any obligation to publicly update any forward looking statement. Neither the Company nor I.R MED are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Company Contact:
Limor Davidson Mund
ir@ir-medical.com
https://www.globenewswire.com/news-release/2020/12/29/2151402/0/en/INTERNATIONAL-DISPLAY-ADVERTISING-INC-ANNOUNCES-COMPLETION-OF-REVERSE-MERGER-AND-CLOSING-OF-2-2-MILLION-PRIVATE-PLACEMENT.html
AskMuncher
4 years ago
$IDAD INTERNATIONAL DISPLAY ADVERTISING, INC AND IR MED LTD EXTEND OUTSIDE DATE OF SECURITIES EXCHANGE AGREEMENT
Press Release | 12/15/2020
New York, NY, Dec. 15, 2020 (GLOBE NEWSWIRE) -- International Display Advertising, Inc. (OTCPINK: IDAD) announced today that it and IR Med Ltd., have agreed to extend the outside date of the Securities Exchange Agreement previously announced on September 3, 2020, with respect to the acquisition of IR Med Ltd., until December 25, 2020. The terms of the Securities Purchase Agreement will otherwise remain unchanged. The Company and IR Med Ltd. continue to work as expeditiously as possible to complete the transaction on or prior to the amended outside date.
Legal Notice Regarding Forward-Looking Statements
This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although IDAD believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. IDAD does not undertake any obligation to publicly update any forward looking statement. Neither IDAD nor IR MED are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.
Contacts:
Yoram Drucker
+972-54-471-1171
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
mikesmith3
2 years ago
4C
2 years ago
12Retyr
2 years ago
Golden Cross
3 years ago
RussianBot
4 years ago
Renee
4 years ago
LexTrader
4 years ago
Dasqeezr
4 years ago
Hot Features
Premium
